DURECT Corp (DRRX) PERSIST Phase 3 Trial of POSIMIR Misses Primary Efficacy Endpoint
Tweet Send to a Friend
DURECT Corporation (Nasdaq: DRRX) today reported that PERSIST, the Phase 3 clinical trial for POSIMIRĀ® (SABERĀ®-Bupivacaine), did not meet ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE